Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.

Steger, Guenther G

Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study. [electronic resource] - Clinical breast cancer 02 2018 - e41-e47 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1938-0666

10.1016/j.clbc.2017.05.012 doi


Administration, Oral
Adult
Aged
Antineoplastic Agents, Hormonal--therapeutic use
Antineoplastic Agents, Phytogenic--therapeutic use
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bone Neoplasms--drug therapy
Breast--pathology
Breast Neoplasms--drug therapy
Chemotherapy-Induced Febrile Neutropenia--epidemiology
Disease Progression
Fatigue--chemically induced
Female
Humans
Middle Aged
Progression-Free Survival
Receptors, Estrogen--metabolism
Receptors, Progesterone--metabolism
Treatment Outcome
Vinorelbine--therapeutic use